Literature DB >> 8522287

Frequent expression of FAS/APO-1 in Hodgkin's disease and anaplastic large cell lymphomas.

L Xerri1, N Carbuccia, P Parc, J Hassoun, F Birg.   

Abstract

FAS/APO-1 (CD95) is a membrane glycoprotein belonging to the tumour necrosis factor/nerve growth factor receptor family, and which can trigger apoptosis in some lymphoid cell lines. Immunohistochemistry combined with Northern blotting allowed determination of the pattern of FAS/APO-1 expression in a series of Ki-1 [CD30] positive lymphoid malignancies, including 27 Hodgkin's disease and eight anaplastic large cell lymphomas. CD30 negative tumours used as controls included 27 B-cell non-Hodgkin's lymphomas. 14 T-cell non-Hodgkin's lymphomas, four reactive lymphadenitis, and non-lymphoid tissues. Immunohistochemistry, performed on frozen sections, revealed a strong FAS/APO-1 expression in 25 out of 27 (92%) Hodgkin's disease cases, predominantly in Reed Sternberg cells; 50 to 100% of the neoplastic cells in eight out of (100%) anaplastic large cell lymphoma cases were positive. In contrast, positive FAS/APO-1 immunostaining was observed only in 22 out of 41 (53%) CD30 negative non-Hodgkin's lymphomas. Northern blot analysis detected variable amounts of the FAS/APO-1 transcript in the immunohistochemistry-positive samples. These results suggest possible hyper-expression of FAS/APO-1 (CD95) in Hodgkin's disease and anaplastic large cell lymphomas.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8522287     DOI: 10.1111/j.1365-2559.1995.tb00215.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  10 in total

1.  Low frequency of FAS mutations in Reed-Sternberg cells of Hodgkin's lymphoma.

Authors:  Ewerton M Maggio; Anke Van Den Berg; Debora de Jong; Arjan Diepstra; Sibrand Poppema
Journal:  Am J Pathol       Date:  2003-01       Impact factor: 4.307

2.  Expression of the cellular FLICE-inhibitory protein (c-FLIP) protects Hodgkin's lymphoma cells from autonomous Fas-mediated death.

Authors:  A Dutton; J D O'Neil; A E Milner; G M Reynolds; J Starczynski; J Crocker; L S Young; P G Murray
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-19       Impact factor: 11.205

3.  Correspondence.

Authors:  P L Nguyen
Journal:  Am J Pathol       Date:  1996-07       Impact factor: 4.307

4.  Apoptosis in haematological malignancies.

Authors:  J A DiGiuseppe; M B Kastan
Journal:  J Clin Pathol       Date:  1997-05       Impact factor: 3.411

Review 5.  Fas expression and apoptosis in human B cells.

Authors:  E Schattner; S M Friedman
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

6.  Fas ligand is not only expressed in immune privileged human organs but is also coexpressed with Fas in various epithelial tissues.

Authors:  L Xerri; E Devilard; J Hassoun; C Mawas; F Birg
Journal:  Mol Pathol       Date:  1997-04

7.  Constitutive expression of c-FLIP in Hodgkin and Reed-Sternberg cells.

Authors:  Roman Kurt Thomas; Anne Kallenborn; Claudia Wickenhauser; Joachim Ludwig Schultze; Andreas Draube; Martina Vockerodt; Daniel Re; Volker Diehl; Jürgen Wolf
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

Review 8.  Contribution of the Epstein Barr virus to the molecular pathogenesis of Hodgkin lymphoma.

Authors:  G Kapatai; P Murray
Journal:  J Clin Pathol       Date:  2007-12       Impact factor: 3.411

9.  Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity.

Authors:  Michael Hinz; Petra Lemke; Ioannis Anagnostopoulos; Christine Hacker; Daniel Krappmann; Stephan Mathas; Bernd Dörken; Martin Zenke; Harald Stein; Claus Scheidereit
Journal:  J Exp Med       Date:  2002-09-02       Impact factor: 14.307

10.  c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis.

Authors:  Stephan Mathas; Andreas Lietz; Ioannis Anagnostopoulos; Franziska Hummel; Burkhard Wiesner; Martin Janz; Franziska Jundt; Burkhard Hirsch; Korinna Jöhrens-Leder; Hans-Peter Vornlocher; Kurt Bommert; Harald Stein; Bernd Dörken
Journal:  J Exp Med       Date:  2004-04-12       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.